Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation (Q40352522)

19 September 2017

Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation (English)

1 reference

19 September 2017

Rangatia J

1

1 reference

19 September 2017

Bonnet D

series ordinal

2

1 reference

19 September 2017

language of work or name

1 reference

1 January 2006

1 reference

19 September 2017

1 reference

19 September 2017

20

1 reference

19 September 2017

1

1 reference

19 September 2017

68-76

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403999

19 September 2017

0 references

cites work

Nonrandom chromosomal abnormalities in hematologic disorders of man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Chronic myelogenous leukemia: mechanisms underlying disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

The BCR-ABL story: bench to bedside and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Specific inhibition of bcr-abl gene expression by small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/abl small hairpin RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

CML leukapheresis products can be enriched for CD34+ cells and simultaneously depleted of CD15+ cells using a simple Ab cocktail

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403999

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403999

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference